Please ensure Javascript is enabled for purposes of website accessibility

Another Day, Another Biotech Dilution

By Dave Williamson - Updated Apr 7, 2017 at 12:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dilution is a way of life for investors in development stage biotechs --  a painful reminder of the costs associated with developing promising new treatments. We have seen a series of high-profile dilutions this month, and in this video health care analyst David Williamson touches on all of them, but focuses in on Aeterna Zentaris action from last week.

Many investors are attracted to Aeterna Zentaris and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aeterna Zentaris Inc. Stock Quote
Aeterna Zentaris Inc.
AEZS
$0.20 (3.68%) $0.01
CTI BioPharma Corp. Stock Quote
CTI BioPharma Corp.
CTIC
$4.87 (9.93%) $0.44
Keryx Biopharmaceuticals, Inc. Stock Quote
Keryx Biopharmaceuticals, Inc.
KERX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.